10-Q · May 14, 2026
Candel Therapeutics reported a significant increase in Q1 2026 operating losses, widening from a loss of $8.9 million to $16.3 million year-over-year. The gross margin remains undisclosed, and the company continues to…
Earnings analysis · 10-Q
CADL earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
This excerpt is primarily the risk-factor and other-information section and does not provide quarterly income-statement, balance-sheet, cash-flow, or segment results; therefore those metrics cannot be assessed from the…
Read full summary
This excerpt is primarily the risk-factor and other-information section and does not provide quarterly income-statement, balance-sheet, cash-flow, or segment results; therefore those metrics cannot be assessed from the supplied filing text. Liquidity remains a key support, with $201.6 million of cash expected to fund operations into Q1 2028, but the company reported a $47.8 million six-month net loss and continues to require external financing. Material disclosed risks include debt covenants, potential China-related supply-chain disruption, AI and cybersecurity regulation, dilution, and higher compliance costs beginning in 2027.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Cash runway extends into Q1 2028
Liquidity remains supported by $201.6 million of cash and cash equivalents as of June 30, 2026; management expects this to fund the current operating plan into the first quarter of 2028.
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
-
No material control changes
The company reported no change during the quarter that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
Post-quarter financing adds liquidity
Candel raised $6.3 million of net proceeds through the 2025 ATM Program from June 30 through August 11, 2026, issuing 617,345 shares.
What to watch
-
Continued losses and funding needs
Candel had an accumulated deficit of $278.2 million as of June 30, 2026 and reported a $47.8 million net loss for the six months ended June 30, 2026, versus $2.6 million of net income in the prior-year period.
-
Debt and covenant constraints
The Trinity facility permits aggregate term loans of up to $130.0 million, with $50.0 million outstanding as of June 30, 2026. Covenants may restrict additional indebtedness, acquisitions, investments and other operating actions.
-
China legislation may disrupt supply chain
The company identifies potential exposure from China-related legislation, including the BIOSECURE Act enacted December 18, 2025, which could affect its WuXi stability-testing relationship.
-
AI regulation and cybersecurity exposure
The filing adds or expands risks from artificial intelligence, including compliance with the EU AI Act, for which most provisions become effective August 2, 2026, and potentially significant fines for noncompliance.
-
Upcoming reporting-status transition
Candel expects to lose emerging growth company and smaller reporting company status as of December 31, 2026, increasing disclosure, compliance and professional costs beginning with the first quarter of 2027.
-
Ongoing equity issuance may dilute holders
The company has sold 2,838,894 shares under its 2025 ATM Program for $24.2 million of net proceeds as of June 30, 2026, plus 617,345 shares for $6.3 million through August 11, creating dilution risk.
Management's outlook
The filing states that cash and cash equivalents of $201.6 million as of June 30, 2026 are expected to fund the current operating plan into the first quarter of 2028, consistent with the prior outlook. No numeric revenue or EPS guidance was provided.
Earlier filings 4
10-K · March 12, 2026
Candel Therapeutics (CADL) is a clinical-stage viral immunotherapy company with two platforms (adenovirus and HSV) and a positive pivotal Phase 3 in localized, intermediate- to high-risk prostate cancer (745 patients…
10-Q · November 13, 2025
Candel Therapeutics remains pre-revenue and reported a Q3 2025 net loss per share of $(0.21), missing the consensus of $(0.17). Operating expenses rose materially year-over-year (Q3 R&D $8,461 vs $5,416), while cash…
10-Q · August 14, 2025
Candel Therapeutics remains pre-revenue but reported a material EPS improvement in Q2 2025 (GAAP loss per share of $0.09) versus Q2 2024 (loss per share $0.74), driven primarily by a non‑cash positive revaluation of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.